Literature DB >> 20338818

Characterization of Fasudil in preclinical models of pain.

Janel M Boyce-Rustay1, Gricelda H Simler, Steve McGaraughty, Katharine L Chu, Erica J Wensink, Anil Vasudevan, Prisca Honore.   

Abstract

UNLABELLED: Activation of Rho kinase (ROCK) has been shown to play a role in neuronal regeneration and development of posttraumatic neuropathic pain. The ROCK inhibitor Fasudil, used clinically for the treatment of vasospasm, was used to investigate the analgesic profile of a ROCK inhibitor. Fasudil was evaluated in different preclinical models of neuropathic, osteoarthritic (OA), and inflammatory pain as well as capsaicin-induced acute pain and secondary mechanical hypersensitivity. In addition, Fasudil was tested in in vivo electrophysiology to determine the mechanism by which Fasudil produces analgesia. Fasudil at the highest dose tested (30 mg/kg) significantly attenuated mechanical allodynia in spinal-nerve ligation (SNL; 77%), chronic constriction injury (CCI; 53%), capsaicin-induced secondary mechanical hypersensitivity (63%), sodium iodoacetate-induced OA pain (88%), and capsaicin-induced acute flinching behaviors (56%). However, Fasudil (at 30 mg/kg) failed to attenuate or had only modest effects on inflammatory thermal hyperalgesia following carrageenan injection and mechanical allodynia following Complete Freund's Adjuvant (CFA) injection. Fasudil produced ED(50) of 10.8 mg/kg in the SNL, and 5.7 mg/kg in the OA pain models. The ED(50) and 95% CI could not be obtained in the other models. Furthermore, administration of Fasudil (10 mg/kg, iv) significantly reduced both spontaneous and evoked firing of wide dynamic range (WDR) neurons in SNL, but not sham rats. Finally, Fasudil significantly decreased exploratory behaviors at 30 mg/kg. These results suggest that the acute administration of a ROCK inhibitor produces efficacy in both neuropathic and nociceptive pain states at doses devoid of locomotor side effects, with specific effects on WDR neurons. PERSPECTIVE: In this article, the potential analgesic effects of Fasudil in a range of preclinical pain models were assessed. Fasudil was shown to have efficacy in neuropathic and nociceptive pain models. These findings may help identify new therapeutic treatments for pain in the clinic.
Copyright © 2010 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20338818     DOI: 10.1016/j.jpain.2009.12.014

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  7 in total

1.  Liquid Biopsy-Based Biomarkers of Inflammatory Nociception Identified in Male Rats.

Authors:  Christina R Merritt; Irma E Cisneros; Obdulia Covarrubias-Zambrano; Sonja J Stutz; Massoud Motamedi; Stefan H Bossmann; Kathryn A Cunningham
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

2.  Intrathecal delivery of farnesyl thiosalicylic acid and GW 5074 attenuates hyperalgesia and allodynia in chronic constriction injury-induced neuropathic pain in rats.

Authors:  Amteshwar Singh Jaggi; Nirmal Singh
Journal:  Neurol Sci       Date:  2012-03-02       Impact factor: 3.830

3.  ROCKing Regeneration: Rho Kinase Inhibition as Molecular Target for Neurorestoration.

Authors:  Lars Tönges; Jan-Christoph Koch; Mathias Bähr; Paul Lingor
Journal:  Front Mol Neurosci       Date:  2011-11-03       Impact factor: 5.639

4.  P2Y12 receptor mediates microglial activation via RhoA/ROCK pathway in the trigeminal nucleus caudalis in a mouse model of chronic migraine.

Authors:  Feng Jing; Yixin Zhang; Ting Long; Wei He; Guangcheng Qin; Dunke Zhang; Lixue Chen; Jiying Zhou
Journal:  J Neuroinflammation       Date:  2019-11-13       Impact factor: 8.322

Review 5.  Recent Advances in Pain Management: Relevant Protein Kinases and Their Inhibitors.

Authors:  Francis Giraud; Elisabeth Pereira; Fabrice Anizon; Pascale Moreau
Journal:  Molecules       Date:  2021-05-04       Impact factor: 4.411

Review 6.  Neurovascular unit in chronic pain.

Authors:  Beatrice Mihaela Radu; Placido Bramanti; Francesco Osculati; Maria-Luisa Flonta; Mihai Radu; Giuseppe Bertini; Paolo Francesco Fabene
Journal:  Mediators Inflamm       Date:  2013-06-05       Impact factor: 4.711

7.  Dual effects of Rho-kinase inhibitors on a rat model of inflammatory pain.

Authors:  Patricia Paiva-Lima; Y S Bakhle; Janetti Nogueira Francischi
Journal:  Pain Res Manag       Date:  2014-07-03       Impact factor: 3.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.